PIM
SKYE icon

Platinum Investment Management’s Skye Bioscience SKYE Stock Holding History

Platinum Investment Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162K Hold
29,137
– – 0.04% 85
2026
Q1 		$143K Hold
29,137
– – 0.04% 89
2025
Q4 		$175K Hold
29,137
– – 0.04% 95
2025
Q3 		$916K Sell
29,137
-7,528
-21% -$227K 0.06% 85
2025
Q2 		$1.23M Hold
36,665
– – 0.08% 71
2025
Q1 		$466K Sell
36,665
-17,591
-32% -$384K 0.03% 80
2024
Q4 		$1.23M Sell
54,256
-6,394
-11% -$214K 0.07% 74
2024
Q3 		$1.9M Buy
+60,650
New +$2.72M 0.09% 68

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Platinum Investment Management's SKYE Position: Q2 2026 in Review

Platinum Investment Management held its Skye Bioscience (SKYE) position steady in Q2 2026 at 29,137 shares worth $162K. The position accounts for 0.04% of the portfolio, ranked #85.

Platinum Investment Management first reported a position in SKYE in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.9M in Q3 2024. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • Platinum Investment Management held 29,137 shares of Skye Bioscience worth $162K as of Q2 2026.
  • Platinum Investment Management left its Skye Bioscience share count unchanged in Q2 2026.
  • Skye Bioscience made up 0.04% of Platinum Investment Management's portfolio in Q2 2026, its #85 holding.
  • Platinum Investment Management first reported a position in Skye Bioscience in Q3 2024 and has held it in 8 quarters since.
  • Platinum Investment Management's Skye Bioscience position peaked at $1.9M in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Platinum Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.